Combined Treatment Research: Immuno-Radiotherapy and Chemo-Radiotherapy

Speaker: Dirk De Ruysscher

D. De Ruysscher explains a rationale for combining immunotherapy and radiotherapy (RT): RT itself has immunological effects. He describes the results from small study in melanoma patients, a retrospective analysis and underlines unknown short- and long-term toxicities when combine RT with checkpoint inhibitors and technical aspects of radiation. He also discuss patients with locally-advanced NSCLC and EGFR or ALK alterations treated with chemo-radiotherapy, again a small subset from a retrospective analysis, but first steps for better future understanding.

Discussion Points

  • Toxicities from combining immunotherapy and radiotherapy
  • Chemo-radiotherapy and mutation profile in locally-advanced NSCLC: The prognostic value